DRIVIN G ROWTH - Dr. Reddy's

The generics business
gives Dr. Reddy’s a direct
presence in first world
markets. It has always had an
export focus and has grown
aggressively on the back of a
slew of profitable products,
successfully clearing
inspections by USFDA, MCC
and the MCA. Its path to
value has taken the high risk,
high return route, with a
series of patent challenge
products. Its current focus:
innovate and build both
technological and commercial
skills to build capabilities for
specialty products.
1994
Commenced: Work on
Generics facility dedicated to
US generics market
generics
1997
Submitted: First Abbreviated
New Drug Application (ANDA) for
Ranitidine 75 mg tablets
1998
Regulatory Inspection: By Medical
Control Council, South Africa
USFDA inspection: Ranitidine 75 mg
tablets and Fluoxetine capsules